Total assets exceed 10 billion for the first time! Wuxi AppTec reaches a new milestone in asset scale

WuXi AppTec (603259.SH / 2359.HK) is experiencing a historic expansion of its asset portfolio. As its 2025 performance reaches new heights, the company’s total assets have surpassed 100 billion yuan for the first time, marking a new level of strength and comprehensive capability as a global pharmaceutical R&D infrastructure.

The driving force behind this asset expansion stems from a dual leap in strategic focus and profitability. WuXi AppTec’s 2025 performance report shows that annual revenue reached 45.456 billion yuan, with net profit attributable to shareholders increasing by approximately 102.65% year-over-year. This explosive profit growth directly contributed to an increase in net assets and abundant cash flow, providing the core internal momentum for the rise in asset scale.

The composition of the “100 billion yuan assets” reflects a physical representation of global capacity and leading market position. WuXi AppTec has built a global network covering over 20 R&D and manufacturing bases across Asia, Europe, and North America, including more than 120,000 square meters of GLP laboratories, 4 million liters of small molecule raw material reaction vessels, and 100,000 liters of peptide solid-phase synthesis reactors. These heavy asset investments are the foundation that enables the company to continuously meet the demands for “high-profile drugs.”

Asset quality and growth momentum are being optimized in tandem, creating a long-term competitive moat. The growth in asset scale is not simply about expansion but focused on efficient allocation after concentrating on core CRDMO operations. By divesting non-core businesses, the company further concentrates resources into high-value areas, driving simultaneous improvements in profitability quality and asset efficiency. By the end of 2025, the company’s order backlog reached 58 billion yuan, providing a reliable anchor for future output efficiency of its 100 billion yuan assets.

For investors, surpassing 100 billion yuan in asset scale marks a new stage of development for the company. This not only signifies a qualitative change in financial strength but also indicates comprehensive improvements in global supply chain resilience, technological platform depth, and customer engagement. As pharmaceutical R&D becomes increasingly complex and demands higher capacity and certainty, WuXi AppTec leverages its solid “100 billion yuan foundation” to continuously strengthen its irreplaceable leading position and long-term investment value.